A Combination of Nucala and Corticosteroids Was Shown to Increase Remission in EGPA
qimono / Pixabay

A Combination of Nucala and Corticosteroids Was Shown to Increase Remission in EGPA

Corticosteroids are used to treat a wide variety of inflammatory conditions, with asthma and arthritis acting as examples. However, these drugs can result in a variety of side effects, such…

Continue Reading A Combination of Nucala and Corticosteroids Was Shown to Increase Remission in EGPA
AAD VMX 2021: Sofpironium Bromide Gel Beneficial for Primary Axillary Hyperhidrosis
https://unsplash.com/photos/Rg0KmrUPB_Q

AAD VMX 2021: Sofpironium Bromide Gel Beneficial for Primary Axillary Hyperhidrosis

From April 23 to 25, 2021, the American Academy of Dermatology (AAD) held their 2021 Virtual Meeting Experience (AAD VMX 2021). During the meeting, a variety of dermatology stakeholders discussed…

Continue Reading AAD VMX 2021: Sofpironium Bromide Gel Beneficial for Primary Axillary Hyperhidrosis
New Combination Treatment Demonstrates Improved Survival for Malignant Pleural Mesothelioma Patients
source: pixabay.com

New Combination Treatment Demonstrates Improved Survival for Malignant Pleural Mesothelioma Patients

The EMA has just recommended a combination therapy for patients with malignant pleural mesothelioma (MPM) that is considered unresectable. The treatment regimen includes nivolumab in combination with ipilimumab. This new…

Continue Reading New Combination Treatment Demonstrates Improved Survival for Malignant Pleural Mesothelioma Patients
First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL
[Source: pixabay.com]

First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL

For many patients with diffuse large B-cell lymphoma (DLBCL), one first-line treatment is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, even aggressive chemotherapy is not always enough for patients…

Continue Reading First Patient Dosed in Trial Evaluating Tafasitamib, Lenalidomide, R-CHOP for DLBCL
Biogen’s Recent Progress in Relapsing Multiple Sclerosis Presented at the 2021 Meeting of the AAN
source: pixabay.com

Biogen’s Recent Progress in Relapsing Multiple Sclerosis Presented at the 2021 Meeting of the AAN

According to an article in Biospace, Biogen, a biotechnology company headquartered in Cambridge, Massachusetts, presented new data on its multiple sclerosis (MS) therapies at the virtual Meeting of the American…

Continue Reading Biogen’s Recent Progress in Relapsing Multiple Sclerosis Presented at the 2021 Meeting of the AAN